LPIXEL Announces Initiation of AI System Development for Cell Evaluation with Astellas Pharma

TOKYO–(BUSINESS WIRE)–LPIXEL Inc., a leader in image analysis and processing technology in
life science and medical research, is pleased to announce the initiation
of the artificial intelligence (AI) system development for cell
evaluation with Astellas Pharma Inc. (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D., “Astellas”). During the project, Astellas will
access LPIXEL’s AI-instilled image analysis solution, IMACEL Lab, for
the cell selection and management processes in conducting research on
regenerative medicine and cell therapy.

AI for Cell Culture Quality Control on Regenerative Medicine and Cell
Therapy

In recent years, much attention has been given to regenerative medicine
and cell therapy, which is the field of science aimed at repairing
damaged cells and tissues. The Astellas Institute for Regenerative
Medicine (AIRM), a subsidiary of Astellas, is carrying out
biopharmaceutical research and development including work on
regenerative medicine and cell therapy. In regenerative medicine and
cell therapy, it is essential to maintain and select cells suitable for
treatment. IMACEL Lab will assist in cell selection and maintenance.

About IMACEL Lab

IMACEL Lab aims to solve various needs in life science research and
development, particularly in the medical, pharmaceutical and
agricultural sectors by combining AI with the image analysis
technologies* that the members of the company have been developing ever
since its inception at the University of Tokyo laboratory in the year
2000. As with Astellas, LPIXEL will foster the development of new values
through each of its partnerships.

* IMACEL: A cloud-based bioimage analysis platform for morphological
analysis and image classification (2019) PLOS ONE 14(2): e0212619.https://doi.org/10.1371/journal.pone.0212619

About LPIXEL

Founded in March 2014, LPIXEL is a University of Tokyo spin-off that
hones its expertise in life science image analysis. LPIXEL unifies
artificial intelligence and its image analysis technologies to develop
and provide advanced software for researchers and professionals in the
life science industry, including the medical, pharmaceutical and
agricultural sectors. LPIXEL is currently working in collaboration with
the University of Tokyo, the National Cancer Center Japan, and other
research institutions to further the development of its AI-powered
medical image diagnostic support technology, EIRL. For more information,
please click here.

Contacts

Contact Details
Mariko Takahashi
LPIXEL Inc.
[email protected]